Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Possible......but......the Indonesia and China announcements could have been enough news to create some fresh buying at distressed prices. We'll see.
Nice volume at mid-afternoon: 1,225,000 shares. Crappy day in the market. GTHP stock absorbing sells very well at .22
We're two months past the last FDA deadline but were informed about it by Bill Wells at Guided. He said the FDA was still analyzing data. The company probably has sent the FDA data from all over the world now. I have never fully understood why the initial 2013 rejection happened. I personally would trust scientists at Johns Hopkins and Emory long before I would trust government bureaucrats attached at the hip to the big boys.
Friday morning, April 17. Nice volume in the first hour. Stock is now at .22. Small float. Worldwide acceptance of the product. An approval just might move this thing. I still think a buyout is imminent upon approval. One of the big boys will try to take it out cheaply. I see a fit for either Merck or GE based on history. No reason not to see $10 per share, IMHO, if the company could go-it alone. The product is important enough.
Has Transcenic beaten MVPI to the punch?
It's nice to see some of us enlightened by a new sense of reality. Remember back when the first units were finally assembled? What were we told? Zero-minimal regulatory issues and sales by the end of 2010. The whole "if we build it, people will trample each other to buy it" mentality took over. I reiterate my stance that it is unbelievable that the company wouldn't leverage its success at Belleville. If you all were CEOs of the company, and your flagship product outperformed a real-life situation beyond your wildest dreams.......would you continue to sit on your hands and let the EPA tell you what to do in the absence of real-life follow up testing? I actually appreciate the EPA's coaxing and leading the company with all the petri dish requests. The company obviously was clueless, in the beginning, as to what to send to the EPA. Yet I also believe that twenty successful real life hospital tests would trump 1000 petri dish tests. The EPA might be an unsung hero here, helping the company get out of its own way. Once approved, the insurance industry just might mandate the use of AS at some point. When we lose 200,000 people a year due to HAIs, one would think the insurance industry's eyebrows have been sufficiently raised.
......as long as orders mean the actual unit is sold with a substantial gross margin and not given away (break even) just to get the disposables business.,
I continue to observe that few professional entities even know Asepticsure exists. Have sports arenas, fitness centers, veterinary clinics, hospitals, shipping companies and cruise lines.....in Canada.... been informed that AS is real?
When companies don't do their own marketing jobs, what are shareholders supposed to do after four years: Sit there and take it and watch their own holdings become terribly diluted? We have. Where does it end? LuViva is selling product in approved countries and testing it in several more. That information should be invaluable to a U.S. government agency trying to make up its mind. Why can't Medizone arrange to give it away and make a name for itself?
Gifting an important product to a medical foundation is another way of making hay while the sun shines. In Canada, our old buddies at Can-Med Healthcare did just that......not an AS system but a LuViva scan system. What the two products have in common is that both are approved in Canada but not yet in the U.S. LuViva, however, is approved in the EU. Countries differ in their accounting methods for depreciation, but charitable giving often carries similar advantages to the bottom line.
You're absolutely right, IMHO. The patents, however, can't hurt anything at this point. One never knows what might happen......this thing could take off in an area outside the hospital arena......so I think it's important to have a few extra patents under the belt.
The accumulation of "Intellectual Property" can add value whether or not there are current sales. The St. Onge application was all over the place. It began as a treatment for "air" and then may have branched out a lot farther than the USPTO would allow for one application. MHO only.
Eli....St. Onge is listed as a global supply chain facilitator headquartered in the U.S. Do you know to what the patent office is pertaining when it references St. Onge?
Well, Never, if ya don't test it....it doesn't make any difference anyway, does it.
Other companies have drugs/devices/products that have been approved by the EU and elsewhere but continue to await a green light from our own lethargic, dinosaur regulatory bodies. These companies sell product wherever it is approved and bombard our agencies with test results from multiple locations. Proving to the EPA/FDA that a product works around the world has to speed up the review process.
It's called having a Strategic Plan., and there obviously wasn't one and isn't one.
Do any of the key people noted in this article have any idea that AS even exists? Is there a better opportunity to give away a couple of test runs at these facilities?
Thanks for the clarifications.
There wasn't a whole lot of information let out back in those days. Then, when the 2013 non-approval letter was issued, there was almost total silence. Cartwright coming on board has changed the communications process. When the company received EU approval (based on the U.S. test...go figure)everything started to become proactive...which is a good thing. Doing business and having testing centers around the world is the only way to convince our almighty FDA that it might have made a mistake. Cartwright said there were two initial issues with the older data. He was not convinced the FDA was interpreting the data correctly. The agency also claimed to have an issue, of all things, about how the device was cleansed between uses. Geezil.
The difference this time may be the number of positive cases coming in from several areas of the developed and developing world. There wasn't much information let out by Faupel and the boys in the old days. Cartwright understands the regulatory system a lot better than Faupel ever did. One would think that, with his background with Abbott and GE, he wouldn't be fiddling around here if he didn't think it was worth it. Just my ever so humble opinion.
2+ years horsing around with the EPA before the company found out what the actual testing protocols were supposed to be? It goes beyond frustration. Are we to assume there has been further real life testing beyond Belleville 6-13? If so.....no one knows about it. The company couldn't wait to shout the Belleville results from the rooftops. One test of that nature is not going to convince any regulatory body that a similar result will occur with each application.
A market maker saw no orders coming in and probably made that trade himself/herself to create a bid-ask for the day (it happens all the time with thinly traded small issues). What one should be looking at is the total emptiness of the recent 10k. All we see are expenditures: 400k R&D for Shannon? For what? Are there no specifics on testing to offer us? What happened at the EPA recently? This document is void of anything positive and pertinent to the advancement of the company.
There is more to it than just the cleaning of the device. When the latest application was rejected in the fall of 2013, Dr. Faulpel gave us little pertinent information as to what happened. A few months later, Gene Cartwright was brought in, thank goodness, and got the ball rolling. He said there were initial issues with how the FDA interpreted the test results. His group has been working feverishly to bring the FDA actual new test results from around the globe. I think that's why it's taking longer than normal. The FDA has to be taught to interpret the older test results correctly and, hopefully, the barrage of new results will support the old results better.
How about just the EPA's evaluation of the last set of requested test results. They're out there somewhere.
Have you sent an email to the author of the article about Asepticsure? These people aren't going to find out about it unless shareholders tell them.
GTHP always has been a strange situation. We're not talking invasiveness or side effects here. So, to me, it comes down to two scenarios. The FDA is protecting the big boys as long as it can.....because of the biopsy, pap smear and vaccine business....or there is a definite flaw in the science that skews results. The product, if the reported results are true, is a true game changer in the developing world and parts of the developed world. Cartwright said the Merck vaccine will limit growth in the U.S.....but it still can be used to follow up HPV screening.
Armune is in the business of developing early detection for breast, lung, and prostate cancer. So I don't think the fit is there. Half tongue in cheek: Xenex should be buying Medizone.
.......and now David Esposito is the President and CEO of Armune Bioscience.
It certainly makes sense that Cartwright might have a potential partner or two waiting in the wings. Most of us wouldn't have hung around this long unless a ringer from the pros had been brought on board.
Well....the stock hit a fresh 52 week low today. It's now February 2015. When was the last set of tests submitted to the EPA? How long did it take the EPA to respond last time? The company should, in comparison, have results by now. It's no big deal.....it's just material information concerning the development of a lead product.
Examples: Merck has a vaccine available in this area. GE has a medical product division that makes and sells non-invasive scanners.
One would think approval would mean an immediate buyout by a multinational healthcare company with global distribution capabilities.
......about which we have been informed. Management has withheld material information from us in the past. I keep a record of it. We should have heard from the EPA by now, if the last set of test requirements is any indication.
Thanks for the update. There remain quite a few "what ifs" here.
Jackcross makes some interesting points here. Wouldn't everyone, including current management, prosper from allowing a person with industry savvy to take over as an actual employee and make this thing go? One would think the two board appointees would be a step in that direction but, so far, we haven't seen much progress in business development.
I'm probably like some of you. I never would have seen anything concerning MVPI had it not been for the spam ads all over IHUB. So I bit the bullet and spent some time doing a little research. I need the board's help getting a few things straight. MVPI has a bunch of patents, but they aren't being utilized to create revenues at this time....right or wrong? The short/intermediate term...and possibly long term best prospects depend on winning a patent infringement suit against Google.....right or wrong? I am looking for tangible assets and a business plan that would point to ongoing revenue streams. What have I missed here? I guess it's a little tough to get excited about a tiny organization trying to stand on the foot of one of the big guys like Google. What is really here besides the hype of possibly winning a lawsuit? Pertinent, business oriented answers are appreciated.
Something else quite important was omitted from the December Chairman's Message. Look at the Asepticsure Page on the Google listings for Medizone. There's a section titled "Research and Trial Results". I offer this direct quote:
"Medizone is currently preparing for a large-scale multi-hospital trial at sites in Canada. It is anticipated that this trial will commence in Q1,2014."
We needed to hear those results in the December message. The question remains.....what happened this time? If any question could be answered going forward, it would have to revolve around why there is no real world testing in markets already approved. This isn't rocket science, people. It's basic business with the need for a little more truth.
Waiting for regulatory approval means that an item cannot be SOLD. Can it be given away with proper authorization? Caponi would be in a prime position to request a waiver in order to have AS decontaminate some HAI afflicted rooms among his many hospitals. So would any other healthcare CEO.....if they knew AS existed.
Historically, management has bristled at the thought of more direct shareholder involvement. The real problem, however, is the long term lack of engagement by management itself. Everyone protecting management's position knows the score but continues to subsidize the status quo instead of investing in real company progress. Along with buying cheap PPL's, why won't the insiders make a true investment in the future of Medizone by funding diversified real world tests in Canada? We're led to think that progress is happening on a monthly basis on several fronts when the truth of the matter is the company is continuing to sit on its hands and spend little/zero money on the development of AS. What other shareholder group would tolerate this chronic ineffectiveness? The BOD needs to Direct.
What would be the "plan" if Santa Claus hadn't dropped a KSA inquiry down the chimney? Real life testing creates the results that helps formulate a basic business plan that can tell the owners how many machines a particular hospital might need and how often the rooms might have to be decontaminated. Climate and other variables may exist. One size may not fit all. Had a testing sequence been established in Canada over the last three years, who knows....? KSA might have ordered a couple hundred AS units by now. It has nothing to do with AS selling itself (it hasn't sold itself so far), but it has a lot to do with establishing the protocols that are needed to be able to SELL the machine to someone (because they're not trampling each other to buy it on their own). It's the basic "feature and benefit" scenario. The three main people who should be responsible for marketing never have gone out of their way to test in real life for commercialization. One of them actually told us to our faces in a recent video that commercialization was not his priority.
I pointed out, several months ago, a non-invasive diagnostic test for cervical cancer that is being used in the developing world and is now being embraced in part of the developed world. A test center is being set up in Canada with none other than C3 (it's NOT approved there yet) as the potential distributor. The test has EU approval (based on the U.S. test) and is approved in Mexico and Central and South America. Why hasn't a test center for Asepticsure been set up in Canada? Canada could have been a test center powerhouse for Asepticsure over the last three years. Yet no money was spent to develop something that important to the future of the company. Canada was mentioned so little in this week's Chairman's Letter that, to someone reading it for the first time, the person would have no idea Medizone has had an approved product up there.